Tris Pharmaceuticals Recalls Infants’ Ibuprofen
December 5, 2018Tecentriq Receives New Indication
December 6, 2018Symjepi to Launch at Lower Cost than EpiPen Generic
December 6, 2018 – Sandoz has announced that Symjepi® (epinephrine) 0.3mg injection will launch in the United States during the first quarter of 2019 at a list price of $250 per pack – more than 16% less than the list price of Mylan and Teva’s generics for the EpiPen® (epinephrine) 0.3mg auto-injector. Each pack contains two doses of Symjepi.
Like EpiPen and similar products, Symjepi is indicated to provide emergency treatment for allergic reactions and anaphylaxis. Sandoz announced the $250 list price shortly after Teva’s launch of a generic to Mylan’s EpiPen. Teva’s generic has a wholesale acquisition cost (WAC) or list price of $300 per two-dose pack. Mylan’s authorized generic for the EpiPen carries the same price.
Symjepi received FDA approval in September 2018.
